OncoPrecision key facts
as of Oct 2026- Developer of a patient micro avatar platform designed to get the cancer therapy to the right patient.
- OncoPrecision is valued at approximately $18.0M as of Oct 2026 (last reported valuation).
- It has raised $8.7M; the latest was Seed Round ($4.5M) in Oct 2025.
- Notable investors include SOSV, Endless Frontier Labs, IndieBio, New York Ventures, Creative Ventures — 8 tracked in total.
- Status: Privately Held (backing).
OncoPrecision's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch OncoPrecision: the Monday email on marks, rounds and moves
OncoPrecision funding rounds
No funding rounds for OncoPrecision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
OncoPrecision valuation
OncoPrecision's last reported valuation was $18 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
OncoPrecision investors
8 investors are on record for OncoPrecision, including SOSV, Endless Frontier Labs, IndieBio and New York Ventures.
About OncoPrecision
Developer of a patient micro avatar platform designed to get the cancer therapy to the right patient. The company's platform leverages single-cell high-throughput biology machine learning to provide comprehensive patient-derived phenotypic biomarkers to tailor cancer therapy across modalities and dramatically improve patient success, enabling oncologists to make data-driven decisions based on patient-derived samples.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 25
- Website
- oncoprecision.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.